GGrantIndex
Sort

326,823 grants matching clinical trial

Biology & Transplantation of the Human Stem Cell

$2,072,348
Philip McGlave · University Of Minnesota · P01 · FY2006 · CA

Vascular remodeling in patients with rare genetic disorders

$2,072,321
Manfred Boehm · National Heart, Lung, And Blood Institute · ZIA · FY2024 · HL

Normal and Neoplastic Growth in the Brain

$2,072,072
Suzanne J Baker · St. Jude Children'S Research Hospital · P01 · FY2016 · CA

Simian Vaccine Evaluation Unit: Operation of a Nonhuman Primate Breeding Colony

$2,072,034
Francois Villinger · University Of Louisiana At Lafayette · N01 · FY2023 · AI

Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge

$2,071,892
Brenda Marie Sandmaier · Fred Hutchinson Cancer Center · P01 · FY2022 · CA

Immune Tolerance Network: Food Allergy

$2,071,809
Jeffrey A Bluestone · University Of California, San Francisco · N01 · FY2009 · AI

PATHOGENESIS AND TREATMENT OF ACUTE HIV INFECTION

$2,071,775
Massachusetts General Hospital · U01 · FY2002 · AI

Basic to Clinical Molecular Neurobiology of Nicotinic Receptors in Schizophrenia

$2,071,759
Robert Freedman · University Of Colorado Denver · P50 · FY2010 · MH

Growth Factor Imaging and Photoimmunotherapy

$2,071,751
Peter L. Choyke · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA

PACIFIC NORTHWEST PROSTATE CANCER SPORE

$2,071,402
Fred Hutchinson Cancer Research Center · P50 · FY2002 · CA

Novel Therapeutic Strategies in Human Myeloid Leukemias

$2,071,388
Dana-Farber Cancer Institute · P01 · FY2003 · CA

Microbicide Development Program (MDP)

$2,071,249
Peter A Anton · University Of California Los Angeles · U19 · FY2009 · AI

Barber-Pharmacist Coordination to Improve Blood Pressure Management in Black Men

$2,071,138
Ronald G Victor · Cedars-Sinai Medical Center · R01 · FY2014 · HL

Phase 1 and Phase 2 Clinical Trials of Agents for Cancer Prevention

$2,071,000
Paul J Limburg · Mayo Clinic Rochester · N01 · FY2009 · CA

Regulatory Support for Cancer Prevention Agent Development

$2,070,388
Caroline C Sigman · Ccs Associates, Inc. · N01 · FY2014 · CA

The University of Texas MD Anderson Cancer Center SPORE in Melanoma

$2,070,386
Michael Davies · University Of Tx Md Anderson Can Ctr · P50 · FY2023 · CA

Prostate Section

$2,070,275
Peter Pinto · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Melanoma and Skin Cancer Program SPORE

$2,070,180
Hassane M Zarour · University Of Pittsburgh At Pittsburgh · P50 · FY2022 · CA

Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer

$2,069,846
Roy S Herbst · Yale University · P50 · FY2023 · CA

Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers

$2,069,565
Steven Mark Albelda · University Of Pennsylvania · P01 · FY2019 · CA

Malaria Pathogenesis in young children and vaccine discovery

$2,069,553
Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI

Preclinical drug development in pancreatic cancer

$2,069,338
Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

SPORE in Brain Cancer

$2,069,263
Frederick F Lang · University Of Tx Md Anderson Can Ctr · P50 · FY2019 · CA

Roles Of Brain Neuroimmune System In Neurodegeneration

$2,069,209
Jau-Shyong Shyong Hong · National Institute Of Environmental Health Sciences · ZIA · FY2015 · ES

Administrative Core A

$2,069,128
Benjamin Levine Ebert · Dana-Farber Cancer Inst · P50 · FY2020 · CA